BMC Cancer (Apr 2018)

Cancer patients’ knowledge about their disease and treatment before, during and after treatment: a prospective, longitudinal study

  • Ola Berger,
  • Bjørn Henning Grønberg,
  • Jon Håvard Loge,
  • Stein Kaasa,
  • Kari Sand

DOI
https://doi.org/10.1186/s12885-018-4164-5
Journal volume & issue
Vol. 18, no. 1
pp. 1 – 11

Abstract

Read online

Abstract Background Knowledge about disease and treatment is necessary before patients can consent to treatment. One of the few established instruments for evaluating whether sufficient information has been provided, is the EORTC QLQ-INFO25 questionnaire which was developed to measure how patients perceive information. The aim of this study was to investigate whether cancer patients’ level of knowledge about their disease and treatment was associated with their perception of and satisfaction with the information. Methods Breast cancer patients referred for adjuvant chemotherapy and prostate cancer patients referred for curative radiotherapy were included. Level of knowledge about their disease and treatment was measured using study-specific questionnaires. Patients’ perception of and satisfaction with the received information was assessed using EORTC QLQ-INFO25. Assessments were done before the first consultation with an oncologist (T1), after the consultation (T2) and 8 weeks after start of treatment (T3). Results Ninety eight patients were enrolled. Patients with higher education, daily Internet access and in paid employment had the highest baseline knowledge scores. The mean knowledge score increased significantly (T1: 16.4; T2: 20.8; T3: 21.3; p < 0.001.). During the same period, the patients reported on the INFO25 a significant, positive increase in how much information they had received, and that they were more satisfied with the information. Conclusions Patients’ knowledge increased significantly during the study period, and they reported that they felt better informed and were more satisfied with the information, suggesting that EORTC QLQ-INFO25 might be used to evaluate cancer patients’ level of knowledge about their disease and treatment. Trial registration ClinicalTrials.gov identifier: NCT01699672. Date of registration: September 21, 2012.

Keywords